COMP <GO>
RXRX vs ADMA // EV/EBITDA & P/E VALUATION
Recursion Pharmaceuticals Inc. (NASDAQ) VS. ADMA Biologics Inc (NASDAQ) • 15-METRIC TALLY: RXRX 1
— ADMA 10
■ METRIC PARITY
LAST: $4.24 (-2.53%) • MKT CAP: $2.53B
valuation
—
LAST: $11.75 (+4.17%) • MKT CAP: $2.63B
valuation
12.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RXRX VS. ADMA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RXRX | ADMA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 5.00% | 57.40% | -52.40 | ADMA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.90% | -67.90 | ADMA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 12.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.95% | 1.06% | -16.01 | ADMA | /fcf-yield <GO> |
| Operating Margin | -60.00% | 37.50% | -97.50 | ADMA | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.80% | -88.80 | ADMA | /net-margins <GO> |
| Revenue Growth (YoY) | 26.90% | 19.60% | +7.30 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.59 | 12.98 | -11.39 | ADMA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ADMA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.1 | 64.1 | -7.98 | ADMA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 15.0x | +17.00 | ADMA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.53B | $2.63B | -$101.0M | ADMA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RXRX REV | ADMA REV | RXRX GROSS % | ADMA GROSS % | RXRX FCF | ADMA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $74.7M | $510.2M | 5.0% | 57.4% | -$378.3M | $27.8M |
| FY 2024 | $58.8M | $426.5M | 23.1% | 51.5% | -$372.9M | $110.4M |
| FY 2023 | $44.6M | $258.2M | — | — | -$289.8M | $8.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RXRX // BETA 1.00
ADMA // BETA —